millions of data points per variable over the course of months and years, and really somehow assimilate that in our heads to predict how business is going to change in the next minute or the next day.”
Via Science’s technology, on the other hand, automates the generation of hypotheses and tests billions of them to generate predictive models of what causes certain things to happen. This is potentially useful in a wide variety of fields, of course, but in order to launch successful startups, Via is going to have to find the markets in which there is enough demand for its technology. GNS has found such customers as Biogen, Johnson & Johnson (NYSE:[[ticker:JNJ]]), Pfizer (NYSE:[[ticker:PFE]]), and one undisclosed healthcare payer. Fina, which raised $4.5 million in a Series A funding round last December, is on its way in the financial world. Where will the next startup focus?
Hill says he expects to launch a new startup in the next 6 months to a year that serves consumer-facing companies that manage many product transactions. Via Science plans to make money on royalties from such subsidiaries and projects with other companies that want to apply its technology for specific issues. In fact, it has already begun work with an undisclosed consumer products company to apply its analytics technology to aid in new product launches, Hill says.
Hill expects that the startups Via incubates will eventually raise capital from outside investors, as Fina did last year. We’ll see whether a new startup emerges via Via in the months to come.
